Hypericum perforatum protects against hepatic injury induced by carbon tetrachloride

Comparative Clinical Pathology

Volumn 21, Issue 6, 2012, Pages 1149-1157

  Abdel Salam, Omar M E ^a   Sleem, Amany A ^a   Shaffie, Nermeen ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Carbon tetrachloride; Hypericum perforatum; Liver; Rat

Indexed keywords

EID: 85028118616     PISSN: 16185641     EISSN: 1618565X     Source Type: Journal    
DOI: 10.1007/s00580-011-1252-1     Document Type: Article

References (74)

1. Abdel-Salam OME (2005) Anti-inflammatory, antinociceptive, and gastric effects of Hypericum perforatum in rats. TheScientificWorld J 5: 586-595.
2. Bean P (2002) The use of alternative medicine in the treatment of hepatitis C. Am Clin Lab 21: 19-21.
3. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620-1624.
4. Belfield A, Goldberg DM (1971) Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme 12: 561-573.
5. Beutler E, Duron O, Kelly BM (1963) Improved method for the determination of blood glutathione. J Lab Clin Med 61: 882-890.
6. Bork PM, Bacher S, Schmitz ML, Kaspers U, Heinrich M (1999) Hypericin as a non-antioxidant inhibitor of NF-kappa B. Planta Med 65: 297-300.
7. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M (2000) Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression. A double-blind, randomized, pilot study. Clin Ther 22: 411-419.
8. Buchholzer ML, Dvorak C, Chatterjee SS, Klein J (2002) Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort. J Pharmacol Exp Ther 301: 714-719.
9. Butterweck V, Bockers T, Korte B, Wittkowski W, Winterhoff H (2001) Long-term effects of St. John's wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Res 930: 21-29.
10. Calapai G, Crupi A, Firenzuoli F, Inferrera G, Squadrito F, Parisi A, De-Sarro G, Caputi A (2001a) Serotonin, norepinephrine and dopamine involvement in the antidepressant action of Hypericum perforatum. Pharmacopsychiatry 34: 45-49.
11. Calapai G, Crupi A, Firenzuoli F, Inferrera G, Ciliberto G, Parisi A, De Sarro G, Caputi AP (2001b) Interleukin-6 involvement in antidepressant action of Hypericum perforatum. Pharmacopsychiatry 34(Suppl 1): S8-S10.
12. Cnubben N, Rietjens I, Wortelboer H, van Zanden J, van Bladeren P (2001) The interplay of glutathione-related processes in antioxidant defense. Environ Toxicol Pharmacol 10: 141-152.
13. Corcoran GB, Mitchell JR, Vaishnav YN, Horing EC (1980) Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol 18: 536-542.
14. Crowley LV (1967) The Reitman-Frankel colorimetric transaminase procedure in suspected myocardial infarction. Clin Chem 13: 482-487.
15. De La Puerta R, Martinez E, Bravo L, Ahumada MC (1996) Effect of silymarin on different acute inflammation models and on leukocyte migration. J Pharm Pharmacol 48: 968-970.
16. Dost T, Ozkayran H, Gokalp F, Yenisey C, Birincioglu M (2009) The effect of Hypericum perforatum (St. John's wort) on experimental colitis in rat. Dig Dis Sci 54: 1214-1221.
17. El-Sherbiny DA, Khalifa AE, Attia AS, Eldenshary D (2003) Hypericum perforatum extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnestic dose of scopolamine. Pharmacol Biochem Behav 76: 525-533.
18. Farghali H, Kamenikova L, Hynie S, Kmonickova E (2000) Silymarin effects on intracellular calcium and cytotoxicity: a study in perfused rat hepatocytes after oxidative stress injury. Pharmacol Res 41: 231-237.
19. Fehér J, Lengyel G (2009) Silymarin in the treatment of chronic liver diseases: past and future. J Clin Exp Med 3: 403-413.
20. Fehér J, Lengyel G, Blázovics A (1998) Oxidative stress in the liver and biliary tract diseases. Scand J Gastroenterol 228: 38-46.
21. Feisst C, Werz O (2004) Suppression of receptor-mediated Ca2+ mobilization and functional leukocyte responses by hyperforin. Biochem Pharmacol 67: 1531-1539.
22. Ferguson JW, Dover AR, Chia S, Cruden NLM, Hayes PC, Newby DE (2006) Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut 55: 542-546.
23. Flora K, Hahn M, Rosen H, Benner K (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93: 139-143.
24. Freeman BA, Crapo JD (1982) Biology of disease: free radicals and tissue injury. Lab Invest 47: 412-426.
25. Gal A, Wogan GN (1996) Mutagenesis associated with nitric oxide production in transgenic SJL mice. Proc Natl Acad Sci USA 93: 15102-15107.
26. Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJP, Roberts SK (2006) Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 21: 275-280.
27. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J (1993) Increased serum nitrite and nitrate levels in patients with cirrhosis: relation to endotoxemia. Hepatology 18: 1139-1143.
28. Gupta OP, Sing S, Bani S, Sharma N, Malhotra S, Gupta BD, Banerjee SK, Handa SS (2000) Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine 7: 21-24.
29. Hagymasi K, Kocsis I, Lugasi A, Feher J, Blazovics A (2002) Extrahepatic biliary obstruction: can silymarin protect liver function? Phytother Res 16(Suppl 1): S78-S80.
30. Halliwell B (2001) Free radicals and other reactive species in disease. In: Nature encyclopaedia of life sciences. Nature Publishing Group, London, pp 246-253.
31. Herrine SK (2002) Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 136: 747-757.
32. Iwai S, Karim R, Kitano M, Sukata T, Min W, Morimura K, Wanibuchi H, Seki S, Fukushima S (2002) Role of oxidative DNA damage caused by carbon tetrachloride-induced liver injury-enhancement of MeIQ-induced glutathione S-transferase placental form-positive foci in rats. J Cancer Lett 179: 15-24.
33. Jia JD, Bauer M, Cho JJ, Ruehl M, Milani S, Boigk G, Riecken EO, Schuppan D (2001) Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 35: 392-398.
34. Keating GM, Curran MP (2003) Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63: 701-730.
35. Kientsch U, Burgi S, Ruedeberg C, Probst S, Honegger UE (2001) St. John's wort extract Ze 117 (Hypericum perforatum) inhibits norepinephrine and serotonin uptake into rat brain slices and reduces 3-adrenoceptor numbers on cultured rat brain cells. Pharmacopsychiatry 34(1): S56-S60.
36. Kiewert C, Buchholzer ML, Hartmann J, Chatterjee SS, Klein J (2004) Stimulation of hippocampal acetylcholine release by hyperforin, a constituent of St. John's wort. Neurosci Lett 364: 195-198.
37. Kleinert H, Boissel JP, Schwarz PM, Förstermann U (2000) Regulation of the expression of nitric oxide synthase isoforms. In: Ignarro LJ (ed) Nitric oxide: biology and pathobiology. Academic, New York, pp 105-128.
38. Kumar V, Singh PN, Bhattacharya SK (2001) Anti-inflammatory and analgesic activity of Indian Hypericum perforatum L. Indian J Exp Biol 39: 339-343.
39. Kumar V, Mdzinarishvili A, Kiewert C, Abbruscato T, Bickel U, van der Schyf CJ, Klein J (2006) NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's wort. J Pharmacol Sci 102: 47-54.
40. Kunkel DB (1985) Updating acetaminophen toxicity. Emerg Med 17: 111-125.
41. Lang JP, Michel L, Halleguen O (2002) Treatment of affective disorder in hepatitis C. A prospective study in 50 patients. Ann Med Interne Paris 153: 22-30.
42. Lang JP, Meyer N, Doffoel M (2003) Benefits of a preventive psychiatric accompaniment in patients hepatitis C virus seropositive (HCV): prospective study concerning 39 patients (article in French). Encephale 29(4 Pt 1): 362-365.
43. Lee PY, McCay PB, Hornbrook KR (1982) Evidence for carbon tetrachloride-induced lipid peroxidation in mouse liver. Biochem Pharmacol 31: 405-409.
44. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM (2003) Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 37: 336-339.
45. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D (1996) St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ 313: 253-258.
46. Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez Mendizabal M, Blanco E, Sanchez de la Cuesta F (2002) Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther 40: 2-8.
47. Mannucci C, Pieratti A, Firenzuoli F, Caputi AP, Calapai G (2007) Serotonin mediates beneficial effects of Hypericum perforatum on nicotine withdrawal signs. Phytomedicine 14: 645-651.
48. Matsumoto A, Ogura K, Hirata Y, Kakoki M, Watanabe F, Takenaka K, Shiratori Y, Momomura S, Omata M (1995) Increased nitric oxide in the exhaled air of patients with decompensated liver cirrhosis. Ann Intern Med 123: 110-113.
49. Mayer KE, Myers RP, Lee SS (2005) Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 12: 559-567.
50. Melino G, Bernassola F, Knight RA, Corasaniti MT, Nistico G, Finazzi-Agro A (1997) S-nitrosylation regulates apoptosis. Nature (London) 388: 432-3.
51. Miranda KM, Espey MG, Wink DA (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5: 62-71.
52. Mizumoto M, Arii S, Furutani M, Nakamura T, Ishigami S, Monden K, Ishiguro S, Fujita S, Imamura M (1997) NO as an indicator of portal hemodynamics and the role of iNOS in increased NO production in CCl4-induced liver cirrhosis. J Surg Res 70: 124-133.
53. Montosi G, Garuti C, Iannone A, Pietrangelo A (1998) Spatial and temporal dynamics of hepatic stellate cell activation. Am J Pathol 152: 1319-1326.
54. Muriel P (1998) Nitric oxide protection of rat liver from lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride. Biochem Pharmacol 56: 773-779.
55. Muriel P, Mourelle M (1990) Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J Appl Toxicol 10: 275-9.
56. Muriel P, Alba N, Pérez-Alvarez VM, Shibayama M, Tsutsumi VK (2001) Comp Biochem Physiol C Toxicol Pharmacol 130: 219-226.
57. Nahrstedt A (2000) Antidepressant constituents of Hypericum perforatum. In: Chrubasik S, Roufogalis BD (eds) Herbal medicinal products for the treatment of pain. Southern Cross University, Lismore, pp 144-153.
58. Nguyen HA, Miller AI, Dieperink E, Willenbring ML, Tetrick LL, Durfee JM, Ewing SL, Ho SB (2001) Spectrum of disease in U. S. veteran patients with hepatitis C. Am J Gastroenterol 97: 1813-1820.
59. Pabuccuoglu A, Konyalioglu S, Bas M, Meral GE (2003) The in vitro effects of Hypericum species on human leukocyte myeloperoxidase activity. J Ethnopharmacol 87: 89-92.
60. Paget GE, Barnes JM (1964) Toxicity testing. In: Laurence DR, Bacharach AL (eds) Evaluation of drug activities pharmacometics. Academic, London, pp 1-135.
61. Parés A, Planas R, Torres M, Caballería J, Viver JM, Acero D, Panés J, Rigau J, Santos J, Rodés (1998) Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 28: 615-621.
62. Poli G (2000) Pathogenesis of liver fibrosis: role of oxidative stress. Mol Asp Med 21: 49-98.
63. Raso GM, Pacilio M, Di Carlo G, Esposito E, Pinto L, Meli R (2002) In-vivo and in-vitro anti-inflammatory effect of Echinacea purpurea and Hypericum perforatum. J Pharm Pharmacol 54: 1379-1383.
64. Rommelspacher H, Siemanowitz B, Mannel M (2001) Acute and chronic actions of a dry methanolic extract of Hypericum perforatum and a hyperforin-rich extract on dopaminergic and serotonergic neurones in rat nucleus accumbens. Pharmacopsychiatry 34(Suppl 1): S119-S126.
65. Roz N, Mazur Y, Hirshfeld A, Rehavi M (2002) Inhibition of vesicular uptake of monoamines by hyperforin. Life Sci 71: 2227-2237.
66. Ruedeberg C, Wiesmann UN, Brattstroem A, Honegger UE (2010) Hypericum perforatum L. (St John's wort) extract Ze 117 inhibits dopamine re-uptake in rat striatal brain slices. An implication for use in smoking cessation treatment? Phytother Res 24: 249-251.
67. Sato Y, Yoneda M, Nakamura K, Makino I, Terano A (2003) Protective effect of central thyrotropin-releasing hormone on carbon tetrachloride-induced acute hepatocellular necrosis in rats. J Hepatol 39: 47-54.
68. Schulte-Löbbert S, Holoubek G, Müller WE, Schubert-Zsilavecz M, Wurglics M (2004) Comparison of the synaptosomal uptake inhibition of serotonin by St John's wort products. J Pharm Pharmacol 56: 813-818.
69. Weber LW, Boll M, Stampfl A (2003) Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 33: 105-136.
70. Wellington K, Jarvis B (2000) Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15: 465-489.
71. Woelk H (2000) Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ 321: 536-539.
72. Wu CG, Chamuleau RA, Bosch KS, Frederiks WM (1993) Protective effect of silymarin on rat liver injury induced by ischemia. Virchows Arch B Cell Pathol 64: 259-263.
73. Yoneda M, Tamori K, Sato Y, Yokohama S, Nakamura K, Makino I (1997) Central thyrotropin-releasing hormone stimulates hepatic DNA synthesis in rats. Hepatology 26: 1203-1208.
74. Zanoli P (2004) Role of hyperforin in the pharmacological activities of St. John's wort. CNS Drug Rev 10: 203-218.